Viveve Medical Inc (PK:VIVE)

Business Focus: Advanced Medical Equipment & Technology

Get the company report for the most recent outlook updated daily

Jan 17, 2023 06:30 am ET

Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq

Dec 15, 2022 08:28 am ET

Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023

Dec 01, 2022 08:28 am ET

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial

Nov 10, 2022 04:02 pm ET

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET today

Oct 27, 2022 08:28 am ET

Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Oct 04, 2022 08:28 am ET

Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence

Sep 27, 2022 08:28 am ET

Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout

New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in Women

Sep 22, 2022 08:28 am ET

Viveve to Participate in Ladenburg Thalmann Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve corporate presentation and provide an update on progress of the Company's SUI clinical development program. He will also meet with investment community members during the conference.

Sep 15, 2022 08:28 am ET

Viveve to Participate in Alliance Global Partners Virtual MedTech Conference

ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's operations including progress of its SUI clinical development program and will meet with investment community members during the virtual conference.

Sep 01, 2022 08:28 am ET

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the hybrid conference.

Aug 11, 2022 04:01 pm ET

Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips

Jul 28, 2022 04:28 pm ET

Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Jul 12, 2022 08:28 am ET

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.

May 17, 2022 04:28 pm ET

Viveve to Participate in H.C. Wainwright Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the hybrid conference.

May 17, 2022 08:28 am ET

Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women

May 12, 2022 04:01 pm ET

Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips

Apr 28, 2022 08:28 am ET

Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022

ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 12, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Mar 17, 2022 04:01 pm ET

Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth

Mar 03, 2022 08:28 am ET

Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Jan 13, 2022 08:28 am ET

Healthcare Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices

Viveve SVP Suzon Lommel named to list for second consecutive year for efforts to advance innovative technologies to treat stress urinary incontinence in women

Jan 04, 2022 08:28 am ET

Viveve to Participate in H.C. Wainwright BIOCONNECT Conference

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright BIOCONNECT Conference, January 10 - 13, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference.

Dec 14, 2021 08:28 am ET

Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence

Major milestone achieved in Company's advance toward a new U.S. SUI indication

Nov 11, 2021 04:02 pm ET

Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday.

Nov 02, 2021 08:28 am ET

Viveve to Host Conference Call on November 11, 2021 to Report Third Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Oct 28, 2021 08:28 am ET

Viveve Announces Issuance of New Device and Methods Patent in U.S

Issuance further expands and strengthens Company's intellectual property portfolio

Sep 23, 2021 08:28 am ET

Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence

Sep 07, 2021 08:28 am ET

Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 - 15, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference.

Aug 12, 2021 04:01 pm ET

Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Total revenue of $1.7M reported for Q2

Aug 05, 2021 08:28 am ET

Viveve to Host Conference Call on August 12, 2021 to Report Second Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 12, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Aug 03, 2021 08:28 am ET

Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve's dual-energy technology device and method. The awarded patent further strengthens the Company's intellectual property portfolio.

Jul 07, 2021 08:28 am ET

Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure

New code approved by American Medical Association and supported by key medical societies

Jul 06, 2021 08:28 am ET

Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, July 13 - 14, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the virtual conference.

Jun 10, 2021 08:28 am ET

Viveve Announces Issuance of New Device and Methods Patent in U.S.

ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 10,980,596 for Viveve's dual-energy technology device. The awarded patent further strengthens the Company's intellectual property portfolio and expands its patent claims in the U.S.

Jun 02, 2021 04:05 pm ET

Viveve Announces Adjournment of Annual Meeting

ENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders for a second time due to a lack of quorum. The adjourned meeting will be held at 12:00 PM Eastern Time on Wednesday, June 23, 2021. The adjourned meeting will also be a "virtual" meeting of stockholders. The record date for the annual meeting is March 15, 2021. A stockholder may use one of the following simple methods to vote:

May 13, 2021 04:02 pm ET

Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update

Pivotal SUI PURSUIT trial enrollment underway and accelerating

May 11, 2021 12:30 pm ET

Viveve Announces Adjournment of Annual Meeting

ENGLEWOOD, CO / ACCESSWIRE / May 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due to a lack of quorum. The adjourned meeting will be held at 12:00 PM Eastern Time on Wednesday, June 2, 2021. The adjourned meeting will also be a "virtual" meeting of stockholders. The record date for the annual meeting is March 15, 2021. A stockholder may use one of the following simple methods to vote:

May 06, 2021 08:28 am ET

Viveve To Host Conference Call on May 13, 2021 To Report First Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / May 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 13, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Apr 01, 2021 08:28 am ET

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve's dual-energy technology device. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.

Mar 18, 2021 04:02 pm ET

Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update

Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today

Mar 02, 2021 08:28 am ET

Viveve to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

ENGLEWOOD, CO / ACCESSWIRE / March 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, March 9 - 10, 2021. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the conference. Due to the coronavirus pandemic, all presentations and meetings will be virtual at the conference.

Feb 18, 2021 04:02 pm ET

Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020

ENGLEWOOD, CO / ACCESSWIRE / February 18, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced topline financial results for the quarter ended December 31, 2020. Based on fourth-quarter 2020 estimated total revenue of $1.9 million, a continued reduction in operating expenses, and a strengthened cash position following the close of the Company's recent upsized financing of $27.6 million in gross proceeds, Viveve is positioned with the capital resources to support operations through year-end 2022, including the

Feb 09, 2021 08:28 am ET

Viveve Recognized for Leadership in Appointing Women to Board of Directors

Colorado Women on Boards Coalition names Viveve as top Colorado public company

Feb 02, 2021 08:28 am ET

Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent

ENGLEWOOD, CO / ACCESSWIRE / February 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office (KIPO) recently issued Korean Patent No. 10-2197234 titled, Vaginal Remodeling Device and Method. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's largest commercial markets.

Jan 29, 2021 08:31 am ET

Thinking about buying stock in Nokia, Sorrento Therapeutics, BlackBerry, Viveve Medical, or Jaguar Health?

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, SRNE, BB, VIVE, and JAGX.

Jan 28, 2021 08:28 am ET

Viveve Regulatory Executive Named Among Top 25 Women Leaders in Medical Devices

Healthcare Technology Report award recognizes outstanding contributions by SVP Suzon Lommel to advance innovative technologies that can transform patient outcomes

Jan 21, 2021 08:28 am ET

Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence

ENGLEWOOD, CO / ACCESSWIRE / January 21, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has initiated its multicenter, randomized, double-blinded, sham-controlled trial entitled Prospective U.S. Radiofrequency SUI Trial (PURSUIT). The protocol of the PURSUIT Trial reflects changes to the study design that were approved by the U.S. Food and Drug Administration (FDA) in December 2020, including an increase in size to 390 subjects across 30 U.S. investigational sites and better-defined inclusion/exclus

Jan 19, 2021 04:02 pm ET

Viveve Announces Closing of an Upsized $27.6 Million Underwritten Public Offering and Exercise of Over-Allotment Option

ENGLEWOOD, CO / ACCESSWIRE / January 19, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $27.6 million, which includes the exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve.

Jan 14, 2021 08:30 am ET

Viveve Announces Pricing of Upsized $24 Million Underwritten Public Offering

ENGLEWOOD, CO / ACCESSWIRE / January 14, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an upsized underwritten public offering of units for gross proceeds of approximately $24 Million (or $27.6 million if the underwriters exercise their option to purchase additional shares) prior to deducting underwriting discounts and commissions and offering expenses payable by Viveve.

Dec 17, 2020 08:28 am ET

Viveve Regains Compliance with NASDAQ Continued Listing Rules

ENGLEWOOD, CO / ACCESSWIRE / December 17, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on December 16, 2020 that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Accordingly, Viveve is in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Ma

Dec 10, 2020 08:28 am ET

Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol

ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that the Company's proposed changes to the study design of its pivotal PURSUIT trial were approved by the U.S. Food and Drug Administration (FDA.) The Company submitted certain protocol amendments to the FDA in October intended to strengthen the overall study and improve the ability to use data from the study to support a clear assessment of the primary endpoint. Viveve plans to initiate the PURSUIT trial

Dec 03, 2020 08:28 am ET

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Approval strengthens supply chain and reduces manufacturing costs for consumable component used with Viveve's Cryogen-cooled Monopolar Radiofrequency technology

Dec 02, 2020 07:30 am ET

Thinking about buying stock in Aurora Cannabis, Pfizer, Viveve Medical, NetApp, or iBio?

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, PFE, VIVE, NTAP, and IBIO.

Nov 12, 2020 04:01 pm ET

Viveve Reports Third Quarter 2020 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 12, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2020, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Nov 10, 2020 08:28 am ET

Viveve to Participate in Alliance Group Partners Virtual Healthcare Symposium

ENGLEWOOD, CO / ACCESSWIRE / November 10, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Alliance Group Partners Virtual Healthcare Symposium on November 19, 2020. Mr. Durbin will meet with members of the investment community in virtual one-on-one meetings during the symposium.

Nov 05, 2020 08:28 am ET

Viveve to Host Conference Call on November 12, 2020 to Report Third Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 5, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2020 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 12, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day.

Oct 30, 2020 08:28 am ET

Viveve Appoints New Independent Board Director

ENGLEWOOD, CO / ACCESSWIRE / October 30, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Sharon Collins Presnell, Ph.D. has joined the Viveve board of directors and its audit committee, effective October 28, 2020. The appointment of Dr. Presnell brings the company in compliance with the corporate governance requirements under Listing Rules 5605(b)(1) and 5605(c)(2) of the Nasdaq Stock Market.

Oct 27, 2020 08:28 am ET

Viveve Launches New Clinical Advisory Board in Urinary Incontinence

Preeminent urology and urogynecology experts to help guide and advance the company's pivotal U.S. PURSUIT trial in Stress Urinary Incontinence

Sep 22, 2020 08:28 am ET

Viveve Announces Issuance of Novel U.S. Method Patent for Stress Urinary Incontinence

New patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence

Sep 03, 2020 08:28 am ET

Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 3, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Due to the coronavirus pandemic, all presentations and meetings will be virtual at the conference.

Sep 01, 2020 08:28 am ET

Viveve Announces Exercise of Warrants for $3.6 Million

ENGLEWOOD, CO / ACCESSWIRE / September 1, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced it has received $3.6 million in proceeds from the exercise of Series A and B warrants and Series A-2 and B-2 warrants. The Series A and B warrants were previously issued in Viveve's public offering that closed in November 2019. The Series A-2 and B-2 warrants were issued in connection with Viveve's warrant offering in April 2020. To date, approximately 61% of the total outstanding warrants issued in both offerin

Aug 25, 2020 06:02 am ET

Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial

ENGLEWOOD, CO / ACCESSWIRE / August 25, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced positive primary efficacy data from its three-arm, five-month Stress Urinary Incontinence (SUI) feasibility study to compare Viveve's Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and a cryogen-only sham treatment to an inert sham treatment for mild to moderate SUI in women. Additionally, the Company reported positive outcomes from an in-vivo preclinical study that was conducted to validate its ne

Aug 13, 2020 04:02 pm ET

Viveve Reports Second Quarter 2020 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / August 13, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended June 30, 2020, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Aug 06, 2020 08:28 am ET

Viveve to Host Conference Call on August 13, 2020 to Report Second Quarter 2020 Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / August 6, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2020 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 13, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day.

Jul 14, 2020 08:28 am ET

Viveve Announces Clearance of Viveve 2.0 System in Thailand

Regulatory clearance expands availability of next-generation CMRF system in key Southeast Asia market

Jul 07, 2020 08:28 am ET

Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence

Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Company's SUI feasibility study, which is evaluating a new sham treatment tip

Jun 29, 2020 05:50 pm ET

Viveve Medical Announces Adjournment of Annual Meeting

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time within which to vote. The adjourned meeting will be held at 10:30 AM Eastern Time on Wednesday, July 22, 2020. The adjourned meeting will also be a "virtual" meeting of stockholders. The record date for the annual meeting is May 6, 2020. A stockholder may use one of the following simple methods to vote:

May 14, 2020 04:01 pm ET

Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / May 14, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2020, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

May 07, 2020 08:28 am ET

Viveve to Host Conference Call to Provide Corporate Update and First Quarter 2020 Financial Results on May 14, 2020

ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will provide a corporate update and report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 14, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day.

Apr 17, 2020 08:02 am ET

Viveve Announces Update to Corporate Strategy

Reconfirms plans for near-term focus on Stress Urinary Incontinence clinical strategy

Apr 17, 2020 08:00 am ET

Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds

ENGLEWOOD, CO / ACCESSWIRE / April 17, 2020 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has entered into agreements with several institutional and accredited investors to exercise certain outstanding Series A warrants to purchase an aggregate of up to 4,820,584 shares of common stock and Series B warrants to purchase an aggregate of up to 242,790 shares of common stock raising gross proceeds of approximately $3 million. These warrants were previously issued in Viveve's public

Apr 16, 2020 08:28 am ET

Viveve Announces Approval of Viveve 2.0 System in Canada

Viveve 2.0 System now available throughout North America, Asia, and over 30 European countries

Apr 15, 2020 08:28 am ET

Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence

Proposed pivotal trial reinforces the company's strategic pursuit of label expansion for Cryogen-cooled, Monopolar Radiofrequency (CMRF) technology in SUI indication

Apr 09, 2020 08:28 am ET

Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women

ENGLEWOOD, CO / ACCESSWIRE / April 9, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of the company's proprietary, Cryogen-cooled Monopolar Radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth.

Mar 26, 2020 08:28 am ET

Viveve Announces Clearance of Next Generation 2.0 System in Taiwan

Viveve 2.0 cryogen-cool monopolar radiofrequency technology and consumable treatment tips are now available in the U.S., China, Hong Kong, South Korea, Taiwan and more than 30 European countries

Mar 19, 2020 04:01 pm ET

Viveve Reports Full Year 2019 Financial Results

ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Viveve Medical Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2019. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Mar 12, 2020 08:28 am ET

Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function

Unblinded top-line results of the 12-month U.S. study anticipated in April

Mar 06, 2020 08:28 am ET

Viveve to Host Conference Call to Provide Corporate Update and Year-End 2019 Financial Results on March 19, 2020

ENGLEWOOD, CO / ACCESSWIRE / March 6, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will provide a corporate update and report its year-end 2019 financial results after the close of the U.S. financial markets on Thursday, March 19, 2020. The Company will host a conference call and webcast at 5:00 PM ET the same day.

Mar 04, 2020 08:28 am ET

Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence

ENGLEWOOD, CO / ACCESSWIRE / March 4, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its three-arm, three-month feasibility study to compare Viveve's Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and a cryogen-only sham treatment to an inert sham treatment for the improvement of stress urinary incontinence (SUI) in women. The Investigational Testing Application (ITA) study, approved by the Canadian Ministry of Health, was initiated in January 2020.

Jan 14, 2020 08:28 am ET

Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence

Three-arm, three-month study will compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment

Dec 31, 2019 08:28 am ET

Viveve Announces Compliance with Nasdaq Listing Rules

ENGLEWOOD, CO / ACCESSWIRE / December 31, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and Viveve will continue to trade on the Nasdaq Capital Market.

Dec 18, 2019 08:28 am ET

Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health

Three-arm, three-month study will compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to an inert sham treatment

Dec 10, 2019 08:28 am ET

Viveve Announces Clearance of Next Generation 2.0 System in South Korea

Viveve 2.0 System and consumable treatment tips now commercially available in U.S., European Union, China, and Korea

Dec 03, 2019 08:28 am ET

Viveve Announces Launch of Viveve 2.0 System in China

Paragon Meditech, Viveve's new distribution partner, conducts launch event highlighting advantages of CMRF technology for leading women's health specialists throughout China

Nov 07, 2019 04:02 pm ET

Viveve Reports Third Quarter 2019 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the third quarter ended September 30, 2019, the successful continuation of its commercial recurring revenue model in the U.S., and advances in its stress urinary incontinence (SUI) clinical development program. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Oct 24, 2019 08:02 am ET

Viveve to Host Conference Call to Provide Corporate Update and Third Quarter 2019 Results on November 7, 2019

ENGLEWOOD, CO / ACCESSWIRE / October 24, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2019 financial results after the close of the U.S. financial markets on Thursday, November 7, 2019, and will host a live conference call and webcast to provide a corporate update at 5:00 PM ET the same day.

Oct 16, 2019 09:31 am ET

Thinking about buying stock in Aurora Cannabis, Achillion Pharmaceuticals, Bank of America, Taiwan Semiconductor, or Viveve Medical?

NEW YORK, Oct. 16, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, ACHN, BAC, TSM, and VIVE.

Oct 01, 2019 09:31 am ET

Thinking about buying stock in Apple, Canopy Growth, Cronos Group, PepsiCo, or Viveve Medical?

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, CRON, PEP, and VIVE.

Oct 01, 2019 08:02 am ET

Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing

ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of

Sep 19, 2019 08:28 am ET

Viveve Submits Investigational Testing Application to Conduct Short-Term Feasibility Study in Stress Urinary Incontinence

Three-month study provides strategic path forward in SUI and will compare Viveve's cryogen-cooled monopolar radiofrequency (CMRF) treatment to cryogen-only treatment and to inert sham treatment

Sep 18, 2019 08:28 am ET

Viveve Announces Reverse Stock Split to Regain NASDAQ Compliance

ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that its Board of Directors has approved a one-for-100 reverse stock split of its common stock that is scheduled to become effective after trading closes on September 18, 2019. The company's common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on September 19, 2019. The company's common stock will continue to trade under the symbol &q

Sep 17, 2019 08:28 am ET

Viveve to Present at the Ladenburg Thalmann 2019 Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Ladenburg Thalmann 2019 Healthcare Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference.

Sep 03, 2019 04:02 pm ET

Viveve to Present at the H.C. Wainwright 21st Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the H.C. Wainwright 21st Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference.

Sep 03, 2019 08:28 am ET

Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau

About Viveve

Aug 22, 2019 08:28 am ET

Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions

Company Expands North America Commercial Capabilities

Aug 08, 2019 04:02 pm ET

Viveve Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Revenue for the quarter ended June 30, 2019 totaled $1.1 million compared to revenue of $5.5 million for the same period in 2018. The decrease in revenue was primarily due to the lower sales volumes and the transition of the company’s commercial model to a rental program. Sales in the second quarter of 2019 included four Viveve Systems and approximately 2,200 disposable treatment tips sold globally. Under the company’s new recurring revenue model, which was launched in the U. S. in June 2019, the company placed 24 Viveve Systems. Rental revenue on t

Aug 07, 2019 04:02 pm ET

Viveve Reports Additional Clinical Results of LIBERATE-International Trial for Stress Urinary Incontinence

*Percentage change results based upon observed case data.

Aug 01, 2019 04:28 pm ET

Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019

Jul 22, 2019 04:30 pm ET

Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives

Jun 25, 2019 08:28 am ET

Viveve Announces FDA 510(k) Clearance of Viveve 2.0 Next Generation System in the U.S.

Company also announces expansion of distribution network targeting gynecology practices in the Middle East through partnership with Dansys Group

Jun 11, 2019 08:28 am ET

Viveve to Present at Raymond James Life Sciences and MedTech Conference

ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Raymond James Life Sciences and MedTech Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference.

May 09, 2019 04:02 pm ET

Viveve Reports First Quarter 2019 Financial and Operating Results

- Successful organizational realignment resulting in decreased operating expenses- Significant progress in clinical programs targeting expanded indications in sexual function and stress urinary incontinence

May 02, 2019 08:28 am ET

Viveve to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results on May 9, 2019

ENGLEWOOD, CO / ACCESSWIRE / May 2, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2019 financial and operating results after the close of the U.S. financial markets on Thursday, May 9, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day.

Apr 18, 2019 08:10 am ET

Analysis: Positioning to Benefit within McEwen Mining, P & F Industries, KemPharm, Viveve Medical, Genius Brands International, and Vuzix — Research Highlights Growth, Revenue, and Consolidated Result

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of McEwen Mining Inc. (NYSE:MUX), P & F Industries, Inc. (NASDAQ:PFIN),...

Apr 11, 2019 04:02 pm ET

Viveve Announces CE Mark Clearance for its Next Generation 2.0 Platform in the European Union

Viveve 2.0 system and its consumable treatment tips can now be sold in over 30 countries in addition to the United States

Mar 14, 2019 04:02 pm ET

Viveve Reports Fourth Quarter and Full Year 2018 Financial Results

ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months and full year ended December 31, 2018.

Mar 11, 2019 08:26 am ET

Viveve Completes Enrollment in VIVEVE II Trial

Resultscould support a marketing application for an expanded U.S. indication forimprovement of sexual function in women

Mar 07, 2019 08:26 am ET

Viveve to Host Conference Call to Discuss Fourth Quarter and Year-end 2018 Financial Results and Corporate Update on March 14, 2019

ENGLEWOOD, CO / ACCESSWIRE / March 7, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will report its fourth quarter and year-end 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day.

Mar 05, 2019 08:26 am ET

Viveve to Present at Cowen and Company 39th Annual Health Care Conference

ENGLEWOOD, CO / ACCESSWIRE / March 5, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Cowen and Company 39th Annual Health Care Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference.

Jan 16, 2019 08:28 am ET

Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. The company also...

Jan 03, 2019 08:28 am ET

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has completed enrollment in its LIBERATE-International trial, a multicenter, randomized, double-blinded, sham-controlled...

Dec 20, 2018 04:50 pm ET

Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s...

Dec 11, 2018 04:05 pm ET

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a...

Dec 06, 2018 09:49 pm ET

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of...

Dec 06, 2018 04:03 pm ET

Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

Viveve Medical, Inc. (NASDAQ: VIVE) (“Viveve”), a medical technology company focused on women's intimate health, today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled,...

Dec 06, 2018 04:01 pm ET

Viveve Announces Proposed Public Offering of Shares of Common Stock

Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be...

Nov 29, 2018 08:28 am ET

Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will host a live webcast of its Key Opinion Leader symposium focused on stress urinary incontinence (SUI) on Tuesday,...

Nov 21, 2018 08:20 am ET

New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chuy's Holdings, Inc. (NASDAQ:CHUY), Viveve Medical, Inc....

Nov 15, 2018 04:28 pm ET

Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the company has been included in Deloitte’s 2018 Technology Fast 500, a list of the 500 fastest growing technology, media,...

Nov 08, 2018 05:30 pm ET

Viveve to Present at Stifel 2018 Healthcare Conference

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Stifel 2018 Healthcare Conference on Tuesday,...

Nov 08, 2018 04:02 pm ET

Viveve Reports Third Quarter 2018 Financial Results

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the third quarter ended September 30, 2018. Total revenue for the three months ended September 30, 2018 was...

Nov 01, 2018 08:28 am ET

Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it will report financial results for the third quarter ended September 30, 2018 after the close of the U.S. financial markets...

Sep 25, 2018 08:28 am ET

Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference

Sep 13, 2018 08:28 am ET

Viveve Appoints Two New Independent Board Members

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Steve Basta and Karen Zaderej have joined the Viveve board of directors, effective today. “It is with great pleasure that I...

Sep 11, 2018 08:28 am ET

Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for authorization to begin...

Aug 28, 2018 08:28 am ET

Viveve to Present at 20th Annual Rodman & Renshaw Global Investment Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Rodman Renshaw Global Investment...

Aug 14, 2018 08:28 am ET

Viveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today the initiation of LIBERATE-International, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety...

Aug 09, 2018 04:02 pm ET

Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the second quarter ended June 30, 2018. Total revenue for the three months ended June 30, 2018, was $5.5...

Aug 07, 2018 08:28 am ET

Viveve Announces FDA Approval to Continue VIVEVE II Clinical Study

Aug 02, 2018 08:28 am ET

Viveve to Announce Financial Results for Second Quarter 2018 and Host Conference Call

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, will announce financial results for the second quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial...

Jul 10, 2018 08:28 am ET

Viveve Reports Preliminary Second Quarter 2018 Revenue of $5.5 million

Viveve Medical Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the second quarter ended June 30, 2018. Estimated total product revenue for the three months ended...

Jul 03, 2018 08:28 am ET

Viveve Submits VIVEVE II Clinical Study 30-Day Patient Safety Data to FDA

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has submitted 30-day patient safety data to the U.S. Food and Drug Administration (FDA) for 38 subjects completing the...

Jun 18, 2018 04:13 pm ET

Viveve Reports Positive Six-Month Data from Stress Urinary Incontinence Feasibility Study

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported positive and sustained six-month data from an ongoing single-arm feasibility study using its cryogen-cooled, monopolar...

Jun 04, 2018 08:28 am ET

Viveve Announces Settlement of Patent Infringement Litigation with Thermi

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the patent litigation that it filed in 2016 against ThermiGen, LLC, ThermiAesthetics,...

May 29, 2018 08:24 am ET

Viveve to Present at Jefferies Global Healthcare Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Jefferies Global Healthcare Conference...

May 16, 2018 08:24 am ET

Viveve Announces Initiation of VIVEVE II Clinical Study

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that patient enrollment is underway in the multicenter randomized VIveve Treatment of the Vaginal Introitus to EValuate Safety and...

May 10, 2018 04:07 pm ET

Viveve Reports First Quarter 2018 Financial Results

Viveve Medical Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported its financial results for the quarter ended March 31, 2018. “For the first quarter of 2018, Viveve recorded sales of $3.7...

May 10, 2018 02:06 pm ET

Viveve Appoints Scott Durbin as Chief Executive Officer

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin has been appointed as the company’s Chief Executive Officer, effective immediately. Mr. Durbin, a seasoned...

May 03, 2018 08:28 am ET

Viveve to Announce First Quarter 2018 Financial Results

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced it will report financial results for the first quarter ended March 31, 2018 on Thursday, May 10, 2018 after the close of the U.S....

Mar 19, 2018 08:28 am ET

Viveve Announces FDA Approval of IDE to Conduct VIVEVE II Clinical Study

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced it received approval of its Investigational Device Exemption (IDE) application from the U.S. Food and Drug Administration (FDA)....

Mar 15, 2018 04:02 pm ET

Viveve Reports Fourth Quarter and Full Year 2017 Financial Results

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months and year ended December 31, 2017."Our successful fourth-quarter results completed a remarkable...

Mar 08, 2018 08:28 am ET

Viveve to Announce Financial Results for Fourth Quarter and Year End 2017

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, will announce financial results for the fourth quarter and the full year ended December 31, 2017 on Thursday, March 15, 2018 after the...

Feb 27, 2018 08:28 am ET

Viveve to Present at March Investor Conferences

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Patricia Scheller, chief executive officer and director, will present an update on the company's global development...

Feb 22, 2018 08:28 am ET

Viveve to Participate in BTIG Healthcare Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief financial officer, will participate in the 2018 BTIG Healthcare Conference, February 28th...

Feb 12, 2018 11:00 am ET

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a...

Feb 09, 2018 08:28 am ET

Viveve to Present at Leerink Global Healthcare Conference

Feb 08, 2018 08:01 am ET

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of...

Feb 07, 2018 04:01 pm ET

Viveve Announces Proposed Public Offering of Shares of Common Stock

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be...

Jan 31, 2018 08:28 am ET

Viveve Announces Expansion of CMRF Technology Platform into Stress Urinary Incontinence Market

Viveve Medical, Inc. (NASDAQ: VIVE) (the "Company"), a medical technology company focused on women's intimate health, today announced the expansion of its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform into the stress urinary...

Jan 04, 2018 08:28 am ET

Viveve Announces Preliminary 2017 Fourth Quarter and Year-End Financial Results and Provides 2018 Revenue Guidance

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today reported preliminary financial results for the three months and full year ended December 31, 2017."Viveve has continued its rapid...

Dec 12, 2017 08:28 am ET

Viveve Medical Named One of North America's Fastest Growing Companies

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today announced that the company has been included in Deloitte's 2017 Technology Fast 500, a list of the 500 fastest growing technology, media,...

Dec 05, 2017 08:28 am ET

VIVEVE I Trial Sub-Analysis Published in Journal of Women's Health

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today announced the Journal of Women's Health (JWH) published a sub-analysis of the Female Sexual Functions Index (FSFI) domains from the VIVEVE...

Nov 08, 2017 04:02 pm ET

Viveve Announces Third Quarter 2017 Financial Results

Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today reported its financial results for the quarter ended September 30, 2017. "During the third quarter, we achieved record quarterly sales of...

Nov 02, 2017 08:28 am ET

Viveve to Present at November Investor Conferences

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today announced that Patricia Scheller, chief executive officer, will present at two upcoming investor conferences in New York City. Ms....

Oct 30, 2017 10:05 am ET

Viveve Launches GENEVEVE™ by Viveve Treatment in Canada

Only Health Canada Licensed Radiofrequency Device that Delivers Treatment to Improve Sexual Function

Oct 26, 2017 08:45 am ET

Streetwise Reports Examines Biotech Company that Receives Device Approval in Five More Countries and Revenue Increases 122% YOY

Maxim Group reported on this firm's Q3/17 earnings, as well as its progress in obtaining international regulatory clearances for its medical system.Included in this article is: Viveve Medical Inc. (NASDAQ: VIVE)According to an Oct. 18 research note...

Oct 18, 2017 08:28 am ET

Viveve Releases Preliminary Third Quarter 2017 Financial Results

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today released preliminary financial results for the third quarter ended September 30, 2017.Third Quarter 2017 Preliminary Financial...

Oct 17, 2017 08:28 am ET

Viveve Announces Regulatory Approval for Viveve System in Mexico

Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today announced that it has received approval from the Mexican Regulatory Authority, COFEPRIS, to market the Viveve® System in Mexico for...

Sep 19, 2017 08:28 am ET

Viveve to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the 2017 Ladenburg Thalmann Healthcare Conference, on Tuesday,...

Sep 12, 2017 08:28 am ET

Viveve Announces Additional Regulatory Approvals in Middle East

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approvals for the Viveve® System in Bahrain, Kuwait, and Qatar. The Viveve System, that...

Sep 05, 2017 08:28 am ET

Viveve to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored...

Aug 10, 2017 04:01 pm ET

Viveve Announces Second Quarter 2017 Financial Results and Strategic Partnership with InControl Medical, LLC

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today reported financial results for the second quarter ended June 30, 2017 and announced it has entered into an exclusive distribution agreement...

Aug 08, 2017 09:56 am ET

Streetwise Reports Examines How Loan Provides Driver for Growth for Medical Device Firm

Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth.Included in this article is: Viveve Medical Inc. (NASDAQ: VIVE)In a July 11 report,...

Aug 03, 2017 04:28 pm ET

Viveve to Announce Second Quarter 2017 Financial Highlights

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the second quarter ended June 30, 2017 on Thursday, August 10, 2017 after market close. The Company will also...

Jun 27, 2017 08:28 am ET

Viveve Selected for Inclusion in Russell 2000(R) Index

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company is positioned for inclusion in the Russell 2000 Index following reconstitution of Russell Indexes announced on...

May 30, 2017 08:28 am ET

Viveve to Present at the Jefferies Global Healthcare Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the Jefferies Global Healthcare Conference on June 6, 2017 at 11:30am ET. Ms....

May 25, 2017 08:45 am ET

The Life Sciences Report Examines Viveve Medical's Record-Breaking Quarter

Viveve Medical Inc.'s (NASDAQ: VIVE) Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts.Included in this article is: Viveve Medical Inc.Viveve Medical Inc. released its Q1/17 financials on May 11,...

May 24, 2017 08:28 am ET

Viveve to Participate in the Craig-Hallum Institutional Investor Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a company focused on women's health, today announced that members of its executive leadership will attend the 14th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota on May...

May 23, 2017 04:02 pm ET

Viveve Secures $30 million Debt Financing with CRG

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that it has entered into a senior credit facility with affiliates of CRG LP to retire its existing credit facility and provide...

May 11, 2017 04:02 pm ET

Viveve Reports First Quarter 2017 Financial Results

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today reported financial results for the first quarter ended March 31, 2017."During the first quarter, we continued to exceed commercial...

May 09, 2017 08:28 am ET

Viveve Announces Expanded Indication for Viveve System in South Korea

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approval for an expanded indication for the Viveve® System from the Ministry of Food and...

May 04, 2017 08:28 am ET

Viveve to Announce First Quarter 2017 Financial Highlights

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the first quarter ended March 31, 2017 on Thursday, May 11, 2017 after market close. The Company will also...

Apr 25, 2017 08:28 am ET

US District Court Denies Thermi's Motions to Dismiss Viveve Patent Infringement Suit

Viveve Medical, Inc.'s (NASDAQ: VIVE) wholly-owned subsidiary, Viveve, Inc. ("Viveve"), a medical technology company focused on women's health, today announced that the U.S. District Court for the Eastern District of Texas has denied motions to...

Mar 22, 2017 11:00 am ET

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock at a public offering...

Mar 17, 2017 08:28 am ET

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $4.00 per...

Feb 28, 2017 08:28 am ET

Viveve to Present at Cowen and Company Health Care Conference in March

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8,...

Feb 16, 2017 04:02 pm ET

Viveve Reports Fourth Quarter and Full Year 2016 Financial Results

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today reported financial results for the three months and year ended December 31, 2016."We have continued to exceed our commercial expectations...

Feb 09, 2017 08:28 am ET

Viveve to Announce Financial Results for Fourth Quarter and Year End 2016

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the fourth quarter 2016 and the full year ending December 31, 2016 on Thursday, February 16, 2017 after...

Feb 07, 2017 08:28 am ET

VIVEVE I Clinical Study Results Published in Journal of Sexual Medicine

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced publication of the results of the VIVEVE I clinical study in the Journal of Sexual Medicine (JSM). The article, under the Female...

Feb 03, 2017 08:28 am ET

Viveve Announces Relocation of Corporate Headquarters to Denver, Colorado

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health and wellness, today announced the signing of a lease agreement for the relocation of the company's corporate headquarters to Englewood, Colorado....

Jan 31, 2017 08:28 am ET

Viveve Names Dr. Grant Stevens Chairman of Aesthetic Advisory Board

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that W. Grant Stevens, MD, FACS, has been named chairman of the Company's Aesthetic Advisory Board. Dr. Stevens is the founder...

Jan 26, 2017 08:28 am ET

Viveve Deploys Initial U.S. Commercial Sales Force

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the deployment of their U.S. sales team for commercialization of the Viveve® System throughout the country. The Viveve System...

Jan 24, 2017 08:28 am ET

Viveve Announces Additional Regulatory Approval in Southeast Asia

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approval for the Viveve® System in Malaysia. The Viveve® System is cleared for marketing...

Jan 05, 2017 08:28 am ET

VIVEVE Announces Regulatory Approvals in Colombia and Costa Rica

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the company has received regulatory approvals from the Ministries of Health in Colombia and Costa Rica. In each country the...

Dec 22, 2016 09:00 am ET

The Life Sciences Report Examines Viveve's Technology for Women's Sexual Dysfunction Receiving Regulatory Approval in 49 Countries

The last several months have been active for Viveve Medical Inc. (NASDAQ: VIVE): The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third quarter financial results beat expectations, and the...

Dec 01, 2016 08:28 am ET

VIVEVE I Clinical Study Results Accepted for Publication in Journal of Sexual Medicine

Viveve Medical Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the Journal of Sexual Medicine (JSM) has accepted for publication the results of the VIVEVE I clinical study for the treatment of...

Nov 10, 2016 04:02 pm ET

Viveve(R) Reports Record Third Quarter Financial Results

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today reported financial results for the quarter ended September 30, 2016."The third quarter continued to be a record breaking period for the...

Nov 10, 2016 08:28 am ET

Viveve Announces New Brand Identity GENEVEVE(TM) by Viveve

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a company focused on women's health, today announced the launch of a new brand name for the procedure using the Viveve® System -- GENEVEVE™. A new logo was also unveiled as part of the worldwide...

Nov 03, 2016 08:28 am ET

Viveve(R) to Announce Financial Results for Third Quarter Ending September 30, 2016

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the third quarter ended September 30, 2016 on Thursday, November 10, 2016 after market close. The Company...

Nov 01, 2016 08:28 am ET

Viveve(R) to Present at New York Investor Conferences in November

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at two premier investor conferences in New York City. Ms. Scheller will present...

Oct 21, 2016 04:02 pm ET

Viveve(R) Files Patent Infringement Suit Against Thermi

Viveve Medical, Inc.'s (NASDAQ: VIVE) wholly-owned subsidiary, Viveve, Inc. ("Viveve"), a medical technology company focused on women's health, today filed a patent infringement lawsuit against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red...

Oct 20, 2016 08:28 am ET

Viveve(R) Announces Regulatory Approval for Viveve System in Brazil

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approval in Brazil. The Viveve System is indicated for treatment of the vaginal...

Oct 13, 2016 04:02 pm ET

Viveve(R) Announces Regulatory Approval for Viveve System in U.A.E. and Lebanon

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approvals for the Viveve System in the United Arab Emirates (U.A.E.) and Lebanon. The...

Oct 06, 2016 04:02 pm ET

Viveve(R) Announces FDA 510(k) Clearance for the Viveve System in the U.S.

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the Viveve System has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA). In the United...

Oct 06, 2016 09:00 am ET

The Life Sciences Report Examines Viveve's Treatment for Improving Women's Sexual Function

Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with...

Sep 27, 2016 08:02 am ET

Viveve Submits Investigational Device Exemption (IDE) for VIVEVE II

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced submission of an Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA), under a de novo 510K, for...

Sep 20, 2016 08:28 am ET

Viveve(R) to Present at Ladenburg Thalmann 2016 Healthcare Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the 2016 Ladenburg Thalmann Healthcare Conference, on Tuesday,...

Sep 15, 2016 04:30 pm ET

Viveve(R) Announces Resignation of Brigitte Smith From Company Board of Directors

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Brigitte Smith has resigned as a director of Viveve's Board of Directors, including from her positions as Chairman of the...

Sep 15, 2016 08:28 am ET

Viveve(R) Announces Distribution Agreement for Viveve System With Melon Ltd. in Finland

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced the entry into a distribution agreement for the Viveve System with Melon Ltd., a leading distributor of healthcare and aesthetic...

Sep 08, 2016 08:28 am ET

Viveve(R) Announces Regulatory Approval for Viveve(R) System in Australia and Distribution Partnership with Device Consulting in Australia and New Zealand

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the Company has received regulatory approval for the sale of the Viveve® System from the Therapeutic Goods Administration...

Aug 25, 2016 04:02 pm ET

Viveve(R) to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the 2016 Rodman & Renshaw 18th Annual Global Investment...

Ad blocking detected

Viveve Medical Inc (PK:VIVE)

Business Focus: Advanced Medical Equipment & Technology